Morningstar

ORYZON receives minutes from End-of-Phase II meeting with the FDA on the PORTICO-2 Phase III vafidemstat trial in Borderline Personality Disorder

Agitation-Aggression in Borderline Personality Disorder (BPD) acknowledged as a possible therapeutic indication Oryzon may use STAXI-2 Trait anger as a primary efficacy endpoint for PORTICO-2 ...
Finanznachrichten

Oryzon Genomics, S.A.: ORYZON Announces Submission of Phase III Protocol to FDA to Initiate PORTICO-2 Trial of Vafidemstat in Borderline Personality Disorder (BPD) Patients

PORTICO-2 will employ two clinical outcome measures for aggression: the STAXI-2 Trait Anger scale (patient-reported) as the primary endpoint, and the Overt Aggression Scale-Modified (OAS-M) (clinician ...